WhatFinger

sraeli company expects to begin commercializing its unique assay in 2017, applying for CE clearance in Europe

World’s first blood test to aid diagnosis of Parkinson’s


Doctors diagnose as many as 60,000 new cases of Parkinson’s disease (PD) every year in the United States. Yet diagnosing PD with certainty can take years — long after early signs and symptoms have appeared. The Israeli startup BioShai has a game-changing product on the horizon: PDx, the world’s first simple blood test for the early diagnosis of PD. The test results can be combined with clinical data, providing a more accurate diagnosis to help physicians decide on the best course of treatment at a much earlier stage. More than 10 million people worldwide are living with this chronic and progressive movement disorder caused by the malfunction and death of neurons that produce dopamine, a chemical that coordinates the brain’s control of movement and coordination. “Having a diagnosis at an earlier stage can lead to a more precise treatment and a higher quality of life for the patient,” says BioShai CEO Jennifer Yarden, who has a PhD in medical science and formerly was responsible for clinical and commercial development of diagnostic assays and kits at Glycominds. Yarden is also CEO and cofounder of Curewize Health. -- More...
Read Full Article...

Welcome to CFP’s Comment Section!

The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.

Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.

Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.

We ask only that commenters keep it civil, keep it clean.

Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.

READ OUR Commenting Policy


CFP Comments

Commenting is not available in this channel entry.

Comments


Support Canada Free Press

Donate


Recommended by Canada Free Press


Subscribe

Sponsored
!-- END RC STICKY -->